Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Cymabay Therapeutics Inc (CBAY) USD0.0001

Sell:$3.80 Buy:$3.81 Change: $0.09 (2.31%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.09 (2.31%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.09 (2.31%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The PPARd receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar focuses on treating certain diseases of the liver and a variety of disorders of lipid metabolism.

Contact details

7575 Gateway Blvd Ste 110
United States
+1 (510) 2938800

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$262.19 million
Shares in issue:
69.00 million
United States
US dollar

Key personnel

  • Sujal Shah
    President, Chief Executive Officer, Director
  • Charles McWherter
    Senior Vice President, Chief Scientific Officer
  • Paul Quinlan
    Chief Compliance Officer, General Counsel, Corporate Secretary
  • Daniel Menold
    Vice President - Finance
  • Klara Dickinson
    Chief Regulatory and Quality Assurance
  • Dennis Kim
    Chief Medical Officer
  • Lewis Stuart
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.